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ABSTRACT: The development of cruzain inhibitors has been driven by the
urgent need to develop novel and more eﬀective drugs for the treatment of
Chagas’ disease. Herein, we report the lead optimization of a class of
noncovalent cruzain inhibitors, starting from an inhibitor previously cocrystal-
lized with the enzyme (Ki = 0.8 μM). With the goal of achieving a better
understanding of the structure−activity relationships, we have synthesized and
evaluated a series of over 40 analogues, leading to the development of a very
promising competitive inhibitor (8r, IC50 = 200 nM, Ki = 82 nM).
Investigation of the in vitro trypanocidal activity and preliminary cytotoxicity
revealed the potential of the most potent cruzain inhibitors in guiding further
medicinal chemistry eﬀorts to develop drug candidates for Chagas’ disease.
■ INTRODUCTION
Over a century after its discovery, treating Chagas’ disease still
presents a major challenge. Despite its high impact in Latin
America, where approximately 10 million people are infected
and thousands die annually, nifurtimox and benznidazole are
the only two drugs available.1−4 These drugs exhibit a number
of drawbacks, including serious side eﬀects and low eﬃcacy,
especially in the treatment of the chronic stage of the disease.5
Therefore, there is an urgent need for the development of safe
and eﬀective new medicines to meet the therapeutic needs of
the aﬀected individuals. Cruzain (EC 3.4.22.51), the major
cysteine protease from Trypanosoma cruzi, is essential for
parasite nutrition, metacyclogenesis, immune evasion, and host
cell invasion.6−8 This enzyme, expressed during the parasite life
cycle, is among the most important biological targets for
Chagas’ disease.5,9,10 Moreover, cruzain has been validated
through the development of several classes of inhibitors with
potent trypanocidal activity.
Most cruzain inhibitors were developed on the basis of
knowledge of its substrate speciﬁcity11 and are irreversible
peptidic inhibitors that bind covalently to the enzyme. For
instance, the vinyl sulfone K777 (compound 1), a proof-of-
concept compound, has shown eﬃcacy against parasite cell
cultures12 and mouse13 and dog14 animal models. These results
encouraged the search for new classes of inhibitors through the
application of a variety of techniques, such as identiﬁcation of
quantitative structure−activity relationships (QSARs),15,16
chemical modiﬁcation of hits identiﬁed in substrate library
screening,17 and optimization of compounds discovered by
high-throughput screening (HTS)18 and virtual screening
(VS).19,20 In addition to the traditional irreversible peptidic
compounds, the application of these drug design approaches
allowed the identiﬁcation of potent nonpeptidic inhibitors (e.g.,
compounds 2−5),17,18,21−23 including several compounds that
bind noncovalently to the enzyme (e.g., reversible inhibitors 3−
5)20 (Figure 1). Several crystal structures of complexes of
cruzain with inhibitors have been determined and are
available,18,20,21,24−26 providing a solid basis for the application
of structure-based drug design (SBDD) methods.
On the basis of the structural information available, the
potency of the compound in the low micromolar range (Ki = 2
μM) and its leadlike properties,27 we have selected a previously
described competitive inhibitor (compound 5) of the target
enzyme (PDB ID 3KKU)20 as a starting point for a lead
optimization program. A number of regions of the lead
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molecule were explored, leading to an understanding of crucial
SAR requirements of this series of analogs and to the
development of new inhibitors with anti-T. cruzi activity.
■ RESULTS
Chemistry. α-Phenoxyacetic acids of type 6 were prepared
from corresponding substituted phenols and α-haloacetic acid
following the described procedures (Scheme 1).28,29 Subse-
quent activation of acids of type 6, followed by coupling with 2-
(2-aminoethyl)benzimidazole (7), led to formation of the
target-substituted benzimidazoles 8. Initially, the activation of
acids of type 6 was performed using pivaloyl chloride (PivCl),
but the reaction of 7 with the mixed anhydrides thus generated
was not completely regioselective. Consequently, the coforma-
tion of 2−3 mol % of the undesired pivalamide of 7 was
observed, even at −78 °C. Because this byproduct could not be
eliminated by fractionated precipitation, we sought an
alternative coupling method. The more reactive acyl chlorides
derived from acids of type 6 tended to concomitantly react to a
certain extent with the less reactive secondary NH-group of the
benzimidazole moiety of 7. Nevertheless, the reactivity of the
acyl chlorides was drastically attenuated through their
conversion into corresponding N-hydroxysuccinimide esters.
These active esters selectively reacted with the terminal NH2-
group of 7, leading to the production of the desired
benzimidazoles 8 in yields higher than 90% and with excellent
purity.
To probe the relevance of the benzimidazole moiety for the
cruzain inhibitory activity of compounds of type 8, some related
amides of type 10 and compound 12 were prepared from
selected acids of type 6 (Scheme 2). The amides of 2-
(piperidin-1-yl)ethanamine (9B) or the biogenic amines
tryptamine (9C) and histamine (9D) were prepared analo-
gously to compounds of type 8. In contrast to the results
Figure 1. Structures of compound K777 (1) and other T. cruzi cruzain inhibitors 2−4, including the lead compound 5 employed in this study.
Scheme 1. Synthesis of Benzimidazoles 8a
aReagents and conditions: (a) PivCl, Et3N, DCM, 0 °C, 1 h, then 7, Et3N, THF, −78 °C, 2 h; (b) oxalyl chloride, DMF (cat.), DCM, rt, 2 h, then N-
hydroxysuccinimide, Et3N, DCM, 0 °C to rt, 2 h, then 7, DCM, Et3N, 15 min, rt; (c, for 8u only) Ac2O, Et3N, DCM, 0 °C to rt, overnight; (d) H2,
5% Pd/C, HCl, EtOH, 1 atm, rt, 3 h; (e) Ac2O, Py, DCM, 0 °C, 2 h; (f) NaBH4, EtOH, rt, 2 h; (g) MCPBA, EtOH, rt, overnight. Compound 8d is
the same as the lead compound 5 shown in Figure 1.
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obtained with the amine 7, the reaction of amines 9A−C with
pivaloyl-mixed anhydrides of acids of type 6 showed satisfactory
regioselectivity, and the coformation of undesired pivalamides
was limited to trace amounts only. Then, histamine derivatives
10cD and 10nD were obtained through intermediacy of the
corresponding N-hydroxysuccinimide esters. Compound 12
was obtained from 10jA following a two-step one-pot strategy.
Accordingly, the hydroxyl group attached to the ethylene linker
was ﬁrst mesylated and then replaced with the nucleophilic
thiopyridone 11.30
The o-bromophenoxy moiety of the template compound
(8d) was also substituted with the thiopyridone 11,30 giving
rise to analogues 16E and 16F (Scheme 3). For the synthesis of
these compounds, however, a new synthesis strategy had to be
developed because the α-substituted acetic acid that resulted
from the S-alkylation of 11 with α-bromoacetic acid
(correspondent of 6, structure not shown) could not be
converted into the respective acyl chloride (the strategy
exploited in Scheme 1). To circumvent this limitation, the
active ester 13 was prepared through the straightforward
acylation of N-hydroxysuccinimide with α-chloroacetyl chlor-
ide. Next, amines 7 and 14E were both acylated with 13 to give
the chlorinated intermediates 15E and 15F, which were then
submitted to reaction in situ with 11, leading to the target
compounds 16E and 16F.
The terminal aromatic amide function of bisamides of type
18 was assumed to replace the benzimidazole moiety of the
template compound (8d) to achieve structural simpliﬁcation.
Two diﬀerent strategies were followed to synthesize the key
intermediate acids 17 (Scheme 4). According to the ﬁrst
strategy, the precursor acid 6j was activated with PivCl, and the
resulting mixed anhydride was treated with β-alanine ethyl
ester. However, this reaction showed poor regioselectivity, and
a considerable amount of the undesired pivalamide of β-alanine
ethyl ester was coformed. Nevertheless, after saponiﬁcation of
this mixture of products, the undesired pivaloyl derivative was
rinsed oﬀ with diethyl ether, leaving the pure acid 17j behind.
In the second, more eﬀective strategy, acids 6g, 6n, and 6r were
ﬁrst converted into the respective acyl chlorides and then
esteriﬁed with N-hydroxysuccinimide. The active esters thus
obtained were then converted to the corresponding acids 17g,
17n, and 17r upon reaction with free β-alanine in a binary
system composed of ethyl acetate and water under conditions
of phase transfer catalysis. Afterward, acids 17g, 17j, and 17n
were activated with PivCl, and the resulting mixed anhydrides
were allowed to react with the matching aromatic amine (“G−
L”) to give the respective bisamides 18. The reaction of (less
nucleophilic) aromatic amines showed satisfactory regioselec-
tivity, and coformation of the undesired pivalamides was
minimized.
Scheme 2. Synthesis of Compounds 10 and 12a
aReagents and conditions: (a) PivCl, Et3N, DCM, 0 °C, 1 h, then 9A−C, Et3N, THF, −78 °C, 2 h; (b) oxalyl chloride, DMF (cat.), DCM, rt, 2 h,
then N-hydroxysuccinimide, Et3N, DCM, 0 °C to rt, 2 h, then 9D, DCM, Et3N, 0 °C, 15 min, rt, 2 h; (c) mesyl chloride, Et3N, DCM, 0 °C, 1 h, then
Et3N, DCM, rt, 40 h.
Scheme 3. Synthesis of Compounds 16E and 16Fa
aReagents and conditions: (a) Et3N, DCM, 0 °C, 1 h; (b) Et3N,
DCM, 0 °C to rt, overnight.
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Conversely, the mixed anhydride method proved ineﬀective
for preparation of bisamides 18rM−18rO. Nonetheless, the
low-nucleophilic nitroanilines “M−O” were satisfactorily
acylated with the acyl chlorides generated from the acid 17r.
The bisamides 18rM−18rO were not isolated but rather were
directly converted into the corresponding C-substituted
benzimidazo-1-yl derivatives 19M−O. This transformation
comprised the reduction of the nitro group with metallic iron
in boiling acetic acid31 and the concomitant cyclization of
intermediate amines to the target compounds.32 Following this
one-pot strategy, C-substituted benzimidazoles 19M−19O
were isolated in good yield and excellent purity. However, it
should be noted that the hydrogen atom of the NH-group may
move between both nitrogen atoms within the benzimidazole
moiety. As a result, compounds 19M−19O present two
tautomeric forms in which the 5- and 6-positions are scrambled.
The bisamides 18jJ and 18nK, both bearing an o-hydroxy
group, are amenable to cyclize to the respective benzoxazoles
20j and 20n in reﬂuxing propionic acid.32
Next, the eﬀect of the N-substitution of the benzimidazole
moiety on inhibitory activity was probed. Thus, the NH group
of the benzimidazole system of a set of three selected
compounds (8c, 8g, and 8l) was modiﬁed through N-alkylation
or N-acylation, giving rise to compounds of type 22 (Scheme
5). Moreover, the general role of the amide-carbonyl of
compounds of type 8 in the binding and inhibition of cruzain
was also evaluated. For this purpose, compound 8j was reduced
to the corresponding amine 23j.
Biological Activity and Molecular Modeling. The
biochemical evaluation of the eﬀects of this series of
compounds against the enzyme cruzain allowed a comprehen-
sive description of the SAR for this scaﬀold. Four rounds of
synthesis allowed us to exploit the impact of changes in the
phenyl ring, the modiﬁcations in the linker between the
aromatic rings, and the replacement or modiﬁcation of the
benzimidazole moiety. Such understanding was aided by
molecular modeling studies, which were conducted in parallel
with the enzymatic assays.
We began our investigation using α-phenoxyacetic acid
derivatives (Figure 2, Table 1). Modiﬁcations of the aromatic
ring that occupies the S2 pocket of cruzain were tolerated.
Replacement of the bromine atom by other halogens (8b, 8c,
and 8e) or by a methyl (8j) resulted in a modest decrease in
potency against the enzyme (2−6-fold) relative to the lead
compound 8d, which suggests that bromine has an optimal size
for occupation of the S2 pocket. Additional modiﬁcations with
the electron-withdrawing groups NO2 (8g) and CN (8f) and
with the electron-donor NH2 (8h) in the ortho-position
resulted in, respectively, 15-, 80-, and >100-fold decrease in
potency. The analogue containing the acetylated amine (8i)
substituent was even less potent. A shift of the Br to the meta-
position (8k) resulted in an equally potent compound, whereas
the modiﬁcation to the para-position (8l) caused a 4-fold
decrease in potency. Therefore, it is possible to change the
position of the bromine atom while conserving activity against
cruzain. However, its removal strongly aﬀects the potency
Scheme 4. Synthesis of Compounds 18−20a
aReagents and conditions: (a) for 17j, PivCl, Et3N, THF, 0 °C, 1 h,
then β-alanine ethyl ester hydrochloride, Et3N, THF, −78 °C, 2 h,
then 2 M NaOH (aq), EtOH, rt, 1 h; (b) for 17g, 17n, and 17r, oxalyl
chloride, DMF (cat.), DCM, rt, 2 h, then N-hydroxysuccinimide, Et3N,
DCM, 0 °C, 2 h, then β-alanine, Na2CO3, (n-Bu)4NBr (cat.), ethyl
acetate, H2O, rt 0.5 h; (c) PivCl, Et3N, DCM, 0 °C to rt, 2 h, then
matching amine (G−L), Et3N, THF, −78 °C, 2 h; (d) for 18rM,
18rN, and 18rO, oxalyl chloride, DMF (cat.), DCM, rt, 2 h, then
matching amine (“M−O”), Py, 0 °C, 0.5 h; (e) Fe powder, acetic acid,
n-butanol, reﬂux, 2.5 h; (f) propionic acid, reﬂux, 4.5 h.
Scheme 5. Synthesis of Compounds 22 and 23a
aReagents and conditions: (a) for 22cP, K2CO3, acetonitrile, 60 °C, 24
h; (b) for 22gQ and 22lQ, Py, 4-DMAP (cat.), acetyl chloride, DCM,
0 °C to rt, 4 h; (c) LiAlH4, THF, rt, 3 days.
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because the IC50 value of the unsubstituted analog (8a) was 14-
fold lower than that of the lead compound (8d).
The α-bromo-β-naphthoxyacetic analog (8r), the most
potent compound of this series, showed a 4-fold higher
potency than the lead compound. Again, the importance of the
bromine was demonstrated because the unsubstituted β-
naphthoxy analog 8n was 15-fold less potent than the
brominated version (8r). Conversely, α-naphthoxy (8m) and
β-naphthoxy (8n) analogues exhibited approximately the same
potency. Further modiﬁcations of the naphthoxy moiety, such
as the replacement of bromine with a carboxyaldehyde group
(8o), a hydroxymethylene group (8p), or a hydroxyl group
(8q), were tolerable, although the cruzain inhibitory activity
decreased by at least 1 order of magnitude.
Subsequent investigations concentrated on evaluation of the
impact of modiﬁcations in the linker between the phenyl (or
naphthalene) ring and the benzimidazole moiety (Table 2).
The importance of the ether functionality was demonstrated by
comparing compound 5 with the ether derivative 8s, in which
the oxygen atom was replaced by a methylene group, and also
with compound 8t, in which the oxygen was replaced by a
sulfur atom. These modiﬁcations resulted in 100- and 50-fold
decreases in potency, respectively. Analysis of the crystallo-
graphic binding mode of the lead compound 5 revealed that the
linker oxygen atom forms a dipole−dipole interaction with the
nitrogen atom of the main chain of Gly163 (Figure 2). The
docking results of the synthesized analogues showed that the
sulfur atom of the thioether analogue (8t) could still interact
with this residue, even though the interaction would be weaker
because it involves a weaker hydrogen bond acceptor.
Naturally, when the ether functionality is substituted by a
methylene group (8s), such an interaction would not be
possible. Elongation of the spacer between the ether and the
amide functionalities by adding one methylene group led to
compound 8v, which exhibits no inhibitory activity. On the
basis of the crystallographic binding mode of the lead
compound 8d, modiﬁcations at the amide functionality would
have a signiﬁcant impact on cruzain inhibitory activity. Indeed,
the amine (23j) obtained through reduction of the parent
amide (8j) showed no inhibitory activity against the enzyme.
This drastic change in potency may be explained by the loss of
the hydrogen bond between the carbonyl oxygen and the
nitrogen atom of the main chain of Gly66, an interaction
commonly observed in cruzain-small molecule complex
structures.21 Another possible eﬀect of removing this functional
group is the higher ﬂexibility of the compound, which could
result in a considerable loss of entropy upon formation of the
complex.
Considering that in the inhibitor−enzyme complex, the
benzimidazole moiety is highly exposed to the solvent, we
exploited alternatives to replace this bicyclic heterocycle (Table
Figure 2. Crystallographic binding mode of the lead compound 5
(PDB ID 3KKU).20 Hydrogen bonds are displayed as dashed orange
lines, and the dipole−dipole interaction is displayed as a cyan dashed
line. The residues involved in these interactions are highlighted. The
ﬁgure was prepared using PyMOL.33
Table 1. Structures and Activity Proﬁles of Compounds 8a−
8q against T. cruzi Cruzain
aThe percent inhibition values of the compounds against T. cruzi
cruzain are the average of at least three measurements, and the errors
are within 10%. bThe IC50 values of the compounds against T. cruzi
cruzain were independently determined by obtaining rate measure-
ments in triplicate for at least six inhibitor concentrations. The values
represent the means of at least three individual experiments. ND = not
determined.
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3). Several modiﬁcations were performed, including replace-
ment by a piperidin-1-yl ring (10dB, 10jB, and 10sB), 1H-
indol-3-yl residue (10jC and 10rC), 1H-imidazol-5-yl residue
(10cD and 10nD), a tetrasubstituted pyridine (12), and some
simple acyclic bisamides (18jG, 18jH, 18jJ, 18jK, 18gL, and
18nJ). In all cases, the activity against cruzain was lost,
indicating that the benzimidazole system is essential for cruzain
inhibition. To further evaluate the role of the benzimidazole
system, benzoxazo-2-yl derivatives 20j and 20n were
synthesized. It is worth noting that even this minor structural
change (NH/oxygen exchange) caused a complete loss of
inhibitory activity. The diﬀerence between the activity of
benzimidazo-2-yl and benzoxazo-2-yl derivatives cannot be
easily explained on the basis of the analysis of the crystal
structure of the cruzain−inhibitor complex.
To investigate the tolerance of substituents in the
benzimidazole ring, analogues carrying either N-alkylated
(22cP) or N-acetylated (22gQ and 22lQ) benzimidazole
moieties were synthesized. These modiﬁcations gave rise to
active compounds, although their potency was approximately 1
order of magnitude lower than that of the parent NH-free
analogues (Table 4). Hence, the NH group of the
benzimidazole moiety, which may act as a hydrogen donor, is
not essential for inhibitory activity, even though the entire
benzimidazole moiety seems to be crucial.
We next explored the inﬂuence of steric and/or electronic
eﬀects by synthesizing analogues carrying electron-donating or
-withdrawing groups on the benzimidazole moiety (19N−
19O). These three analogues showed a similar potency against
cruzain when compared with 8r, regardless of the electron-
withdrawing (19N) or electron-donating (19M and 19O)
nature of the substituent.
The results of the SAR analysis are summarized in Figure 3.
On the basis of these results, the design of additional analogues
with potentially higher cruzain potency and aﬃnity is currently
underway. Along these lines, substituents should be linked to
the benzimidazole moiety in a manner that allows them to
occupy either the S1′ or the S3 pocket of the enzyme.
Given the competitive mode of inhibition of lead compound
8d, we expected that the optimized compounds in this series
would also be competitive inhibitors. Through the evaluation of
the cruzain inhibition at several substrate and inhibitor
concentrations, we conﬁrmed that 8r, one of the most potent
compounds in the series, was a competitive inhibitor (Ki = 82
nM), as shown in the Lineweaver−Burk plot (Figure 4).
In Vitro Evaluation of Compound Activity against T.
cruzi. Because some compounds in this series showed potent
inhibitory activity against cruzain, their in vitro activity against
T. cruzi was also evaluated. A set of 17 compounds was assayed
using the standard drug benznidazole (BZ) as a positive
control. Several compounds showed similar or higher
trypanocidal activity than the standard drug. Among them,
lead compound 8d presented an IC50 value of 1.6 μM and was
thus 3-fold more potent than BZ.
Although the phenyl ring of the inhibitor, which binds to the
S2 pocket of the enzyme, is amenable to modiﬁcations that do
not signiﬁcantly aﬀect the inhibitory activity against cruzain,
several such modiﬁcations were highly detrimental to the
trypanocidal activity. For instance, analogues containing
halogens other than bromine in the ortho-position (8b, 8c,
and 8e), those carrying the bromine in the meta-position (8k),
or those containing the α-naphthyl ring (8l) showed no activity
against the parasite. In contrast, replacing the bromine atom
with a cyano (8f), nitro (8g), or a methyl group (8j) or shifting
it to the para-position resulted in compounds with IC50 < 10
μM against T. cruzi. Among the synthesized analogues, the
most potent inhibitor 8r showed a 4-fold higher potency than
lead compound 8d against cruzain. However, 8r was 10-fold
less active in vitro against the parasite than compound 8d. The
N-acetylated compounds 22lQ and 22gQ also showed similar
potencies in this assay. Surprisingly, compound 20j, which
showed only approximately 30% enzyme inhibition at 100 μM,
was quite potent against T. cruzi, with an IC50 value of 2.9 μM.
Pre-Toxicity Assessment. The potency of this compound
series against the enzyme and the parasite encouraged us to
investigate its toxicity proﬁle. Therefore, all compounds
evaluated in vitro against T. cruzi were also submitted to
acute toxicity assays. Each compound was evaluated in one
female BALB/c mouse and administered by the intraperitoneal
route (ip). During a 6-h time period, four doses were injected,
resulting in a cumulative dose of 150 mg/kg (Table 6). The
animals were then observed for 48 h. Mice treated with the
compounds 8j, 8t, 8b, 8f, 8l, 8k, and 8e presented some acute
toxicity signs after the last dose (Table 7); however, after 24 h,
these signs were no longer observed. The preliminary toxicity
assays indicated that all compounds seem to be safe because no
toxicity signs were observed. The only exception was
compound 8e, in which the mouse treated was dead after 48
h, suggesting that this compound may be toxic.
Table 2. Structures and Activity Proﬁles of Derivatives 8s, 8t,
8v, and 23j against T. cruzi Cruzain
aThe percent inhibition values of the compounds against T. cruzi
cruzain are the average of at least three measurements, and the errors
are within 10%. bThe IC50 values of the compounds against T. cruzi
cruzain were independently determined by obtaining rate measure-
ments in triplicate for at least six inhibitor concentrations. The values
represent the means of at least three individual experiments. ND = not
determined.
Journal of Medicinal Chemistry Article
dx.doi.org/10.1021/jm401709b | J. Med. Chem. 2014, 57, 2380−23922385
The assay performed in this study involved only one mouse
per compound to minimize the number of animals tested.
Therefore, the acute toxicity ﬁndings reported here do not have
statistical value. However, they still serve as an important pilot
study to encourage further investigation of this series of
compounds, which could serve as an interesting platform for
the generation of new antichagasic agents.
■ DISCUSSION
Through the combination of drug design, organic synthesis,
molecular modeling, enzymatic and parasitic assays, and toxicity
assessments, this paper contributes to the ﬁeld of Chagas’
disease research by validating a new class of cruzain inhibitors
as promising leads for drug development.
The synthesis of over 40 analogues of the original lead 8r
allowed a comprehensive study of the SARs in this series of
compounds. We were able to characterize and delineate the
functional groups essential for improved potency and selectivity
against cruzain. The SAR studies revealed several useful
structural insights, which are consistent with the known
experimental binding mode20 and molecular modeling results,
thus providing a detailed interpretation of the binding mode
and mechanism of inhibition within this series of inhibitors.
Accordingly, we have shown that the new analogues are
competitive inhibitors, following the mechanism of the original
lead compound.20 Therefore, we provide important data to
guide further SBDD eﬀorts, which we are already undertaking
or planning for subsequent rounds of investigation.
Another important result obtained here was the demon-
stration of biological activity for a class of competitive,
reversible inhibitors of cruzain. Usually, compounds that are
active against T. cruzi are irreversible inhibitors, as demon-
strated in several studies.34−36 Herein, we describe 12
compounds active against the T. cruzi parasite, eight of which
had IC50 values lower than 10 μM. These inhibitors are
candidates for preclinical studies in animal models of the
disease.
Considering the high failure rates of compounds in clinical
trials because of toxicity, it is important to consider this
property. Herein, we show that only one of the compounds
evaluated in mouse models was potentially toxic, and therefore,
this series seems to have a promising safety proﬁle. Because the
studies conducted here are only pilot studies, further assays will
be important to evaluate this property in more detail.
Table 3. Structures and T. cruzi Cruzain Inhibitory Activity Proﬁles of Derivatives with a Replaced Benzimidazole Moiety
aThe percent inhibition values of the compounds against T. cruzi cruzain are the average of at least three measurements, and the errors are within
10%. bThe IC50 values of the compounds against T. cruzi cruzain were independently determined by obtaining rate measurements in triplicate for at
least six inhibitor concentrations. The values represent the means of at least three individual experiments. ND = not determined.
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Taking into account all experiments performed in this study,
compounds 8d (the original lead) and 8r are particularly
promising. 8d had IC50 values of 0.8 μM against T. cruzi cruzain
and 1.6 μM against the parasite, whereas 8r was more potent
against the enzyme (IC50 = 0.2 μM, Ki = 80 nM), and although
less potent against T. cruzi, it was still active (IC50 = 16.2 μM).
The analogue 8r was also highly eﬃcient (LE = 0.4 kcal mol−1/
non-H atom), as an LE = 0.30 mol−1/non-H atom is necessary
to reach low nanomolar aﬃnities with druglike compounds.37
Additionally, the physicochemical properties of both com-
pounds are within the Lipinski rule of 5,38 and the mouse assay
for acute toxicity indicates that they are safe.
■ CONCLUSION
In summary, a new series of benzimidazole derivatives that can
act as trypanocidal cruzain inhibitors was discovered through
structural optimization and SAR analysis, and the series shows
Table 4. Structures and Cruzain Inhibitory Proﬁles of
Compounds Carrying C- or N-Substituted Benzimidazo-2-yl
Residues
aThe percent inhibition values of the compounds against T. cruzi
cruzain are the average of at least three measurements, and the errors
are within 10%. bThe IC50 values of the compounds against T. cruzi
cruzain were independently determined by obtaining rate measure-
ments in triplicate for at least six inhibitor concentrations. The values
represent the means of at least three individual experiments. ND = not
determined.
Figure 3. Summary of SAR investigations for optimization of the lead
compound 5.
Figure 4. Lineweaver−Burk plot for the highly potent inhibitor 8r.
Table 5. In Vitro Activity Proﬁles of the Most Potent
Cruzain Inhibitors against T. cruzi
compd IC50 (μM)
a
8j 2.8 ± 0.7
8s 34.6 ± 2.5
8t >100
8b >100
20j 2.9 ± 0.7
8f 6.5 ± 2.1
8k >100
22lQ 5.3 ± 2.1
8m >100
8d 1.6 ± 0.6
8r 16.2 ± 3.5
8c >100
22cP 11.1 ± 3.2
8g 7.9 ± 2.13
8l 6.7 ± 2.4
8e >100
8n 46.1 ± 6.2
BZ 4.8 ± 0.5
aThe IC50 values of the compounds against the T. cruzi Tulahuen
strain in the in vitro assay represent the means of at least three
individual experiments. BZ = benznidazole (N-benzyl-2-(2-nitro-1H-
imidazol-1-yl)acetamide).
Table 6. Cumulative Doses of Compounds Evaluated against
Mice
time point (h) dose injected (mg/kg) cumulative dose (mg/kg)
0 20 20
2 30 50
4 50 100
6 50 150
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promising inhibitory potency and in vitro activity against the
parasite. These cruzain inhibitors interact noncovalently with
the enzyme, revealing an interesting proﬁle for further lead
optimization and new chemical entity (NCE) discovery. Several
compounds with IC50 values in the nanomolar or low
micromolar range against the enzyme, and in several cases
with activity against T. cruzi at low micromolar concentrations,
were described. The most potent inhibitor, 8r, showed excellent
inhibitory activity (IC50 = 200 nM, Ki = 82 nM) and
considerable in vitro potency against T. cruzi. Furthermore,
the most promising inhibitors showed a good safety proﬁle in
pre-toxicity assays in mice. Together with the SAR description
and the structural information available for lead compound 8d,
these results should foster further development of this series as
leads for the treatment of Chagas’ disease. Structural studies to
characterize new T. cruzi cruzain−inhibitor complexes and
eﬀorts to improve the pharmacodynamic and pharmacokinetic
properties are under way.
■ EXPERIMENTAL SECTION
Chemistry: Materials and Methods. Dichloromethane (DCM),
triethylamine (Et3N), and pyridine (Py) were distilled from CaH2.
Tetrahydrofuran (THF) and diethyl ether were distilled from sodium/
benzophenone. Flash column chromatography was conducted using
silica gel (230−400 mesh). Analytical thin-layer chromatography was
performed on silica gel 60 and GF (5−40-μm thickness) plates, and
the visualization was accomplished using UV light and phosphomo-
lybdic acid followed by heating. 1H and proton-decoupled 13C NMR
spectra were recorded in DMSO-d6, CDCl3, or CD3OD at 250 MHz
(1H) and 60 MHz (13C), 400 MHz (1H) and 100 MHz (13C), 500
MHz (1H) and 125 MHz (13C), or 600 MHz (1H) and 150 MHz
(13C). The chemical shifts (δ) are reported in ppm using
tetramethylsilane (TMS) at 0.00 ppm or the solvent signal as an
internal standard (CDCl3 at 7.26 ppm, CD3OD at 3.30 ppm, and
DMSO-d6 at 2.49 ppm for
1H NMR spectra and CDCl3 at 77.0 ppm,
CD3OD at 49.0 ppm, and DMSO-d6 at for
13C NMR spectra). Data
are reported as follows: s = singlet, d = doublet, t = triplet, q = quartet,
bs = broad singlet, dd = doublet of doublets, ddd = doublet of doublet
of doublets, m = multiplet; coupling constant(s) in Hz; integration.
High-resolution mass spectrometry (HRMS) was performed using the
electrospray ionization (ESI) technique. The parent ions ([M + H]+ or
[M + Na]+) are cited. The purity (≥95%) of all compounds evaluated
in this work was determined by 1H NMR.
Note that the NH-free benzimidazo-2-yl system of compounds of
type 8 presents two possible tautomeric forms (i.e., the hydrogen atom
may shift between both nitrogen atoms). As a result, some carbon
atoms of this moiety usually give broad, low-intensity 13C NMR signal
or no 13C NMR signal at all when spectra are recorded in DMSO-d6.
Most likely, the rate of tautomer interconversion is inﬂuenced by the
water content of DMSO-d6. Upon derivatization of the free NH-group
of the benzimidazo-2-yl moiety (e.g., 22cP, 22lQ, and 22gQ), the
whole set of 13C NMR signals becomes apparent. In contrast, when
the 13C NMR spectrum is recorded in a protic solvent (CD3OD, e.g.,
compound 8v) the NH-free benzimidazo-2-yl system becomes
“symmetric” and is reduced to only four detectable 13C NMR signals.
Synthesis Chemistry. General Procedures for Preparation of
Compounds of Type 8. Method A. The matching 2-phenoxyacetic
acid (6, 15 mmol) was dissolved in absolute DCM (50 mL) containing
dry Et3N (22.5 mmol) at 0 °C under an Ar atmosphere. Neat PivCl
(15 mmol) was added dropwise within 15 min, and a white precipitate
formed and was separated. The slurry was stirred for 20 min, the ice
bath was removed, and then stirring was continued for 1 h. The
mixture containing the crude mixed anhydride was stored at 0 °C. In a
separate reaction ﬂask, commercial 2-(2-aminoethyl)benzimidazole
dihydrochloride (7, 0.20 g, 0.85 mmol) was suspended in absolute
THF under an Ar atmosphere. Dry Et3N (3.06 mmol) was added, and
the mixture stirred until complete dissolution of 2-dihydrochloride
occurred (eventually, gentle warming was required). The THF
solution was cooled down to −78 °C, and the cold DCM solution
containing the crude mixed anhydride (3 mL) was added portionwise
within 15 min. Stirring was continued for 2 h at −78 °C. The reaction
mixture was allowed to warm up to room temperature, and the solvent
blend was evaporated under reduced pressure. The evaporation
residue was portioned between ethyl acetate and water. The organic
layer was washed with water (three times), diluted NaHCO3 solution
(two times), and brine; dried over Na2SO4; and concentrated to
dryness in vacuum. The crude solid product was suspended in diethyl
ether, and the resulting slurry was stirred for 1 h at room temperature.
The precipitate was ﬁltered oﬀ, rinsed with diethyl ether, collected, and
dried in vacuum.
Method B. The matching 2-phenoxyacetic acid (1.5 mmol) was
suspended in absolute DCM (15 mL) at room temperature. A catalytic
amount of N,N-dimethylformamide (DMF, 0.10 mL) was added, and
then neat oxalyl chloride (0.63 g, 5 mmol) was combined portionwise
within 10 min. Stirring was continued until gas evolution ceased. The
clear solution that resulted was cooled down to 0 °C and combined
with solid N-hydroxysuccinimide (0.69 g, 6 mmol), and then neat dry
Et3N (1.52 g, 15 mmol) was added portionwise within 10 min. After
15 min, the mixture was removed from the ice bath, and stirring was
continued for 2 h. The solvent was evaporated in vacuum, and the
solid evaporation residue was partitioned between ethyl acetate and
ice-cold water. The organic layer was washed with cold diluted
NaHCO3 solution and brine, dried over Na2SO4, and concentrated in
vacuum. The crude N-hydroxysuccinimide ester thus obtained was
suspended in diethyl ether (3 mL), and the mixture was stirred at
room temperature (15 min). Hexane (3 mL) was added, and the
mixture was kept in a freezer overnight. The solid was ﬁltered oﬀ,
rinsed with cold diethyl ether, collected, dried in vacuum, and stored.
In a separate reaction ﬂask, commercial 2-(2-aminoethyl)-
benzimidazole dihydrochloride (7, 0.25 g, 1.07 mmol) was suspended
in ordinary DCM (30 mL). Neat, ordinary Et3N (0.36 g, 3.52 mmol)
was added, and the matching solid N-hydroxysuccinimide ester was
added to the clear solution that resulted. The mixture was stirred at
room temperature for 15 min. The solvent was evaporated in vacuum,
and the evaporation residue was portioned between ethyl acetate and
water. The organic layer was washed with diluted NaOH solution and
brine, dried over Na2SO4, and concentrated to dryness in vacuum. The
crude solid product was suspended in diethyl ether, and the resulting
slurry was stirred for 1 h at room temperature. The precipitate was
ﬁltered oﬀ, rinsed with diethyl ether, collected, and dried in vacuum.
Unless otherwise stated, no further puriﬁcation was required.
General Procedures for Preparation of Compounds of Type
10. Method A. The matching 2-phenoxyacetic acid (6, 15 mmol) was
Table 7. Acute Toxicity of Selected Compoundsa
time (h) 8j 8d 8s 8r 8t 8c 8b 22cP 20j 8g 8f 8l 8k 8e 22lQ 8n 8m
0 + + + + + + + + + + + + + + + + +
2 + + + + + + + + + + + + + + + + +
4 + + + + + + + + + + + + + + + + +
6 C + + + + + + + + + C T C C + + +
24 + + + + + + + + + + + + + + + + +
48 + + + + + + + + + + + + + D + + +
aIn vivo assays with BALB/c mice. Key: +, without acute toxicity signs; C, chill; T, thirst; D, death.
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dissolved in absolute DCM (50 mL) containing dry Et3N (22.5 mmol)
at 0 °C under an Ar atmosphere. Neat PivCl (15 mmol) was added
dropwise over 15 min, whereupon a white precipitate separated. The
slurry was stirred for 20 min, the ice bath was removed, and stirring
was continued for 1 h. The mixture containing the crude mixed
anhydride was stored at 0 °C. In a separate reaction ﬂask, the matching
amine of type 9 (2 mmol) was dissolved in absolute THF (10 mL).
Neat, dry Et3N (0.20 g, 2 mmol) was added. The mixture was cooled
down to −78 °C, and then the cold DCM solution containing the
crude mixed anhydride (12 mL, ca. 3.6 mmol) was added portionwise
within 10 min. The mixture was stirred for 2 h. The reaction mixture
was concentrated in vacuum, and the evaporation residue was
portioned between ethyl acetate and water. The organic layer was
washed with water (once), saturated NaHCO3 solution (twice), and
brine; dried over Na2SO4; and concentrated to dryness in vacuum to
give the crude products.
Method B. The matching 2-phenoxyacetic acid (6, 5 mmol) was
suspended in absolute DCM (15 mL) at room temperature. A catalytic
amount of DMF (0.10 mL) was added, and then neat oxalyl chloride
(0.63 g, 5 mmol) was combined portionwise within 10 min. Stirring
continued until gas evolution ceased. The clear solution that resulted
was cooled down to 0 °C, solid N-hydroxysuccinimide (0.69 g, 6
mmol) was combined, and then neat dry Et3N (1.52 g, 15 mmol) was
added portionwise within 10 min. After 15 min, the mixture was
removed from the ice bath, and stirring was continued for 2 h. The
solvent was evaporated in vacuum, and the solid evaporation residue
was partitioned between ethyl acetate and ice-cold water. The organic
layer was washed with cold diluted NaHCO3 solution and brine, dried
over Na2SO4, and concentrated in vacuum. The crude N-
hydroxysuccinimide ester thus obtained was suspended in diethyl
ether (3 mL), and the mixture was stirred at room temperature (15
min). Hexane (3 mL) was added, and the mixture was kept in a freezer
overnight. The solid was ﬁltered oﬀ, rinsed with cold diethyl ether,
collected, dried in vacuum, and stored. In a separate reaction ﬂask,
commercial 2-(1H-imidazol-4-yl)ethanamine dihydrochloride (9D,
0.195 g, 1.06 mmol) was suspended in ordinary ethyl acetate (40
mL). Neat, ordinary Et3N (0.21 g, 2.12 mmol) was added, and the
mixture was stirred for 30 min at room temperature. The matching
solid N-hydroxysuccinimide ester was added, and the mixture was
stirred at room temperature for 15 min. The reaction solution was
washed with water and then extracted with 2 M HCl solution. The
organic phase was discarded. The aqueous phase was alkalinized using
2 M NaOH solution and extracted with ethyl acetate (three times).
The combined organic phases were washed with brine, dried over
Na2SO4, and concentrated to dryness in vacuum. The products were
obtained in pure form, and no puriﬁcation was required.
General Procedures for Preparation of Compounds 16E and
16F. 2,5-Dioxopyrrolidin-1-yl 2-chloroacetate (13). N-Hydroxysuc-
cinimide (1.15 g, 10 mmol) was dissolved in a mixture of absolute
DCM (20 mL) and dry Et3N (1.39 mL, 10 mmol) at 0 °C. Neat 2-
chloroacetyl chloride was combined portionwise within 5 min,
whereupon a white precipitate separated. The mixture was stirred at
0 °C for 1 h. The ice bath was removed, and stirring was continued for
2 h. The reaction mixture was diluted with DCM; washed with ice-cold
water (once), diluted NaHCO3 solution (twice), and brine; dried over
Na2SO4; and concentrated in vacuum. The crude product showed
excellent purity, and no puriﬁcation was performed: 1.20 g (63%), pale
solid; 1H NMR (250 MHz, CDCl3) δ 4.35 (s, 2H), 2.84 (s, 4H);
13C
NMR (60 MHz, CDCl3) δ 168.42, 163.19, 37.79, 25.50.
Typical Procedures for Preparation of Compounds of Type
17. Preparation of N-Hydroxysuccinimide Esters (2,5-Dioxopyrroli-
din-1-yl 2-(2-Nitrophenoxy)acetate). 2-(o-Nitrophenoxy)acetic acid
(1 g, 15 mmol) was suspended in absolute DCM (30 mL) at room
temperature. A catalytic amount of DMF (0.20 mL) was added, and
then neat oxalyl chloride (2.28 g, 18 mmol) was combined portionwise
within 10 min. Stirring was continued until gas evolution ceased. The
clear solution that resulted was cooled to 0 °C, solid N-
hydroxysuccinimide (2.10 g, 18 mmol) was combined, and then
neat dry Et3N (2.27 g, 22.5 mmol) was added portionwise within 10
min; stirring was continued for 1 h at 0 °C. The reaction mixture was
diluted with ordinary DCM (50 mL), acidiﬁed with a few drops of
acetic acid, washed with ice-cold water (once) and then washed with
ice-cold diluted Na2CO3 solution (three times) and brine, dried over
Na2SO4, and concentrated to dryness in vacuum. The crude N-
hydroxysuccinimide ester thus obtained was suspended in diethyl ether
(10 mL), and DCM (1−2 mL) was added. The slurry was vigorously
stirred at room temperature for 1 h and then kept in a freezer
overnight. The solid material was ﬁltered oﬀ, rinsed with diethyl ether,
and dried in vacuum: 3.97 g (90% yield), pale solid; 1H NMR (250
MHz, DMSO-d6) δ 7.90 (m, 1H), 7.67 (m, 1H), 7.37 (m, 1H), 7.20
(m, 1H), 5.24 (s, 2H), 2.82 (s, 4H); 13C NMR (60 MHz, DMSO-d6) δ
169.85, 164.79, 149.49, 139.90, 134.23, 125.10, 122.13, 115.31, 63.86,
25.48.
General Procedures for Preparation of Bisamides 18. The
matching substituted propanoic acid of type 17 (1.0 equiv) was
dissolved in absolute DCM (50 mL) containing dry Et3N (1.0 equiv)
at 0 °C under an Ar atmosphere. Neat PivCl (1.0 equiv) was added
dropwise within 15 min, whereupon a white precipitate separated. The
slurry was stirred for 20 min, and then the ice bath was removed, and
stirring was continued for 1 h. The reaction mixture containing the
mixed anhydride was kept at 0 °C. In a separate reaction ﬂask, the
matching aromatic amines (1.2 equiv of G, H, or L and 2.4 equiv of J
or K) were dissolved in absolute THF under an Ar atmosphere. Dry
Et3N (1.0 equiv) was added, and the solution was cooled to −78 °C.
The cold DCM solution containing the preformed mixed anhydride
was carefully transferred to the reaction mixture by means of a syringe,
and stirring at −78 °C was continued for 2 h. The reaction mixture
was concentrated under reduced pressure. The evaporation residue
was portioned between ethyl acetate and water. The organic layer was
washed with water (three times), diluted NaHCO3 solution (two
times), and brine; dried over Na2SO4; and concentrated to dryness in
vacuum to produce the crude products.
Typical Procedure for Preparation of Compounds 19M−
19O. 2-(1-Bromonaphthalen-2-yloxy)-N-(2-(5-chloro-1H-benzo[d]-
imidazol-2-yl)ethyl)acetamide (19N). The substituted propionic acid
17r (1. 0 g, 2.85 mmol) was suspended in absolute DCM (30 mL) at
room temperature. A catalytic amount of DMF (0.10 mL) was added,
and then neat oxalyl chloride (0.54 g, 4.27 mmol) was combined
portionwise within 10 min. Stirring was continued until gas evolution
ceased (ca. 1 h). The clear solution that resulted was cooled to 0 °C
for addition of solid 4-chloro-2-nitroaniline (N, 0.49 g, 2.85 mmol).
Neat, dry Py (0.69 mL, 8.55 mmol) was then combined portionwise
within 10 min. Stirring was continued at 0 °C for 30 min, acetic acid (2
mL) was added in one shot, and the DCM was evaporated in vacuum.
The wet evaporation residue was suspended in n-butanol (20 mL).
Iron powder (0.48 g, 8.85 mmol) was added, and the slurry was heated
to reﬂux temperature for 3 h. The oil bath was removed, and after
some time, ethyl acetate (150 mL) was carefully added to the still hot
(ca. 80−90 °C) reaction mixture under vigorous stirring. The resulting
dark brown slurry was allowed to cool to room temperature, and the
solid material was ﬁltered out (suction through a paper ﬁlter). The
limpid ﬁltrate was washed with water (three times), diluted aq sodium
carbonate solution (three times), and brine. The organic phase was
vigorously stirred in the presence of anhydrous Na2SO4 for a few
minutes, and then silica gel (ca. 1 g) was added, and stirring continued
for a few minutes. The solid material was ﬁltered oﬀ, and the solution
was concentrated in vacuum. Finally, the bulk part of residual n-
butanol was coevaporated with ethanol. The wet crude product was
suspended in a few milliliters of ethanol, and the slurry was kept in a
freezer overnight. The precipitate was ﬁltered oﬀ, rinsed with cold
ethanol, and dried in vacuum: 735 mg (57% overall yield, based on
acid 17r), pale, amorphous solid, excellent purity according to 1H
NMR; 1H NMR (250 MHz, DMSO-d6) δ 12.10 (bs, 1H), 8.20 (t, 1H,
J ∼ 5 Hz), 8.05 (d, 1H, J = 8.5 Hz), 7.87 (m, 2H), 7.69−7.37 (m, 4H),
7.36−7.26 (m, 1H), 7.20−7.07 (m, 1H), 4.72 (s, 2H), 3.68 (q, 2H, J ∼
6 Hz), 3.04 (t, 2H, J = 6.5 Hz); 13C NMR (100 MHz, DMSO-d6) δ
167.29, 154.60, 154.15, 152.26, 144.22, 142.07, 135.06, 133.11, 132.10,
129.63, 129.19, 128.27, 128.16, 126.14, 126.00, 125.34, 125.26, 124.66,
121.65, 121.21, 119.38, 117.66, 115.30, 112.15, 110.71, 107.69, 68.30,
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36.51, 28.59; HRMS (ES+) m/z ([M + H]+) calcd for
C21H18BrClN3O2 458.0271, found 458.0247.
Typical Procedure for Preparation of Compounds 20j and
20n. N-(2-(Benzo[d]oxazol-2-yl)ethyl)-2-(o-tolyloxy)acetamide
(20j). The bisamide 18jK (0.25 g, 0.76 mmol) was suspended in
propionic acid (3.0 mL), and the slurry was reﬂuxed for 6 h. The
propionic acid was evaporated in vacuum (70 °C, 45 mbar). The wet
evaporation residue was dissolved in diethyl ether, and the ethereal
solution was washed with diluted NaHCO3 solution (three times) and
brine. The ethereal solution was vigorously stirred in the presence of
anhydrous Na2SO4 for a few minutes, and then silica gel (ca. 1 g) was
added, and stirring continued for a few minutes. The solid material was
ﬁltered oﬀ, and the solution was concentrated in vacuum. The liquid
crude product was dissolved in a minimal amount of DCM and
precipitated with hexane. The solvent blend was evaporated to dryness
in vacuum, and the tacky, solid evaporation residue was suspended and
stirred in a blend of diethyl ether and hexane (1:1 v/v). The slurry was
kept in a freezer overnight, and the solid material was ﬁltered oﬀ,
rinsed with fresh cold solvent blend, and dried in vacuum: 150 mg
(64% yield), pale solid; 1H NMR (250 MHz, CDCl3) δ 7.77−7.56 (m,
2H), 7.52−7.40 (m, 1H), 7.37−7.26 (m, 2H), 7.16−7.01 (m, 2H),
6.90−6.78 (m, 1H), 6.71 (d, 1H, J = 8.0 Hz), 4.48, (s, 2H), 3.93 (q,
2H, J = 6.0 Hz), 3.16 (t, 2H, J = 6.0 Hz), 2.24 (s, 3H); 13C NMR (60
MHz, CDCl3) δ 168.40, 164.88, 155.16, 150.73, 140.83, 130.89,
126.96, 126.41, 124.84, 124.31, 121.53, 119.52, 110.91, 110.42, 67.03,
35.04, 28.60, 16.35; HRMS (ES+) m/z ([M + H]+) calcd for
C18H19N2O3 311.1396, found 311.1370.
Procedure for Preparation of Compounds of Type 22. N-(2-
(1 - (But -3 -eny l ) -1H-benzo[d ] imidazo l -2 -y l ) e thy l ) -2 - (2 -
chlorophenoxy)acetamide (22cP). Compound 8c (0.10 g, 0.30
mmol) and potassium carbonate (0.42 g, 3.0 mmol) were suspended
in acetonitrile (10 mL). The mixture was warmed to 60 °C, and 4-
bromobut-1-ene (21P, 0.04 g, 0.30 mmol) was added. The reaction
progress was monitored by TLC (CHCl3/methanol 20:3) every 2 h,
and extra 21P (a huge excess of the alkylating agent was required) was
added until 8c was completely consumed. The acetonitrile was
evaporated under reduced pressure. The evaporation residue was
portioned between diethyl ether and water. The organic layer was
washed with water and brine, dried over Na2SO4, and concentrated to
dryness in vacuum. The tacky crude product was rinsed (three times)
with a blend of diethyl ether and hexane (1:1 v/v): 110 mg (95%
yield), colorless, crystalline solid; 1H NMR (250 MHz, CDCl3) δ 8.04
(t, 1H, J ∼ 5.5 Hz), 7.76−7.66 (m, 1H), 7.35−7.19 (m, 4H), 7.13 (dt,
1H, J = 1.6, 7.9 Hz), 6.91−6.76 (m, 2H), 5.85−5.64 (m, 1H), 5.10−
4.96 (m, 2H), 4.51 (s, 2H), 4.15 (t, 2H, J = 7.2 Hz), 4.02 (q, 2H, J =
6.1 Hz), 3.08 (t, 2H, J = 6.1 Hz), 2.52 (q, 2H, J = 7.2 Hz); 13C NMR
(60 MHz, CDCl3) δ 167.67, 152.69, 152.12, 142.24, 134.74, 133.39,
130.31, 127.69, 122.99, 122.44, 122.34, 122.03, 119.34, 118.46, 113.28,
109.29, 67.73, 43.07, 35.75, 33.78, 27.25; HRMS (ES+) m/z ([M +
H]+) calcd for C21H23N3O2Cl 384.1479, found 384.1416.
Procruzain Expression and Puriﬁcation. Procruzain truncated
at the C-terminal was expressed and puriﬁed using a modiﬁed version
of a previously published protocol.39 Overnight cultures of Escherichia
coli (SG13009) were diluted 10-fold into fresh LB medium containing
ampicillin (100 μg/mL) and kanamycin (50 μg/mL) and cultured for
1 h at 37 °C. Cruzain expression was then induced with 1 mM IPTG
(isopropyl β-D-thiogalactopyranoside), and the cultures were grown
with agitation at 30 °C for 4 h. The cells were harvested by
centrifugation and resuspended in 100 mL of lysis buﬀer (100 mM
sodium phosphate, 10 mM Tris-HCl, 8 M urea ultrapure, pH 8) per
liter of culture. After 1 h of incubation at 4 °C, the solution was
centrifuged, and the supernatant was collected. The soluble fraction
was puriﬁed in a Ni−NTA column (Qiagen) by employing a wash
buﬀer (100 mM sodium phosphate, 10 mM Tris-HCl, 8 M urea
ultrapure, pH 6.3) and eluted with the same buﬀer plus 200 mM
imidazole. The fractions obtained were analyzed in an SDS−PAGE gel
to determine which fractions would be pooled. The puriﬁed protein at
1−2 mg/mL was incubated in 10 mM DTT at 37 °C for 45 min and
immediately diluted 100-fold in ice-cold renaturation buﬀer (100 mM
Tris-HCl, 1 mM EDTA, pH 8, 250 mM L-arginine, 20% glycerol), in
which it was stored at 4 °C for 20 h. Refolded cruzain was then
concentrated to 0.5 mg/mL for activation.
Procruzain Activation and Puriﬁcation of Mature Cruzain.
The enzyme was activated following a previously published protocol.18
Brieﬂy, a 0.5 mg/mL solution of procruzain (in 100 mM sodium
acetate, pH 5.5, 10 mM EDTA, 5 mM DTT, and 1 M NaCl, pH
adjusted to 5.3) was activated at 37 °C. During activation, cruzain
activity was measured at 30 min intervals on the basis of the assay
described below. When the enzyme activity was observed to be stable
over time, and the activity stopped increasing (usually after
approximately 3 h), the solution was transferred to an ice bath.
After activation, the mature enzyme was diluted 20-fold in binding
buﬀer (20 mM sodium phosphate, pH 7.2, 150 mM NaCl) to reduce
the DTT concentration and allow binding to a thiopropyl Sepharose
6B gel (Pharmacia), as previously reported.3 After overnight
incubation at 4 °C, the gel incubated with cruzain was transferred to
a column, and cruzain was eluted with binding buﬀer plus 20 mM
DTT. Fractions containing cruzain, as conﬁrmed by an SDS−PAGE
gel, were pooled. The buﬀer was exchanged with 0.1 M sodium
acetate, pH 5.5, and the solution was stored at −80 °C.
Cruzain Inhibition Assays. Cruzain activity was measured by
monitoring the cleavage of the ﬂuorogenic substrate Z-Phe-Arg-
aminomethylcoumarin (Z-FR-AMC). All cruzain assays were
performed in 0.1 M sodium acetate, pH 5.5, and in the presence of
5 mM dithiothreitol (DTT) and 0.01% Triton X-100.4 The ﬁnal
concentration of cruzain was 1.5 nM, and the substrate concentration
was 5.0 μM (Km = 1.6 μM), except for Ki determination, for which
several substrate concentrations were employed. The assays were
monitored for 5 min, and the activity was calculated on the basis of
initial rates compared with a DMSO control. All assays were
performed in triplicate. Values of IC50 were independently determined
by taking rate measurements for at least six inhibitor concentrations,
each one evaluated in triplicate, and the reported error refers to the
ﬁtting error of the curve. To determine the mechanism of cruzain
inhibition for compound 8r, eight Z-FR-AMC substrate concen-
trations and four inhibitor concentrations (one corresponding to the
IC50 value and the others equivalent to half, twice, and 4-fold IC50)
were used in the assays, each one in triplicate. Kinetic parameters were
determined from the collected data employing the SigmaPlot enzyme
kinetics module. The values represent the means of at least three
individual experiments.
Molecular Docking. Mol2 ﬁles of the docked compounds were
prepared from the corresponding SMILES by upload in the ZINC
Web site.40 The molecules were then docked with the program GOLD
3.141,42 (Cambridge Crystallographic Data Centre, Cambridge, UK)
against the cruzain structure (PDB ID 3KKU).20 Receptor preparation
consisted of removing all crystallographic waters and adding
hydrogens with Sybyl. The active site residues Cys25 and His162
were treated as an ionic pair, with the Cys25 negatively charged and
His162 protonated. Compounds were docked by applying default
GOLD parameters, except that the eﬃciency was changed to 200%
and scaﬀold constraints were added to favor superposition to the
crystallographic atomic coordinates of a substructure of the lead
compound. The generated poses were evaluated using the Goldscore
scoring function.
Parasites and Culture Procedures. Assays were performed using
T. cruzi strain Tulahuen parasites genetically engineered to express the
E. coli β-galactosidase gene, lacZ,43 which catalyzes a colorimetric
reaction with chlorophenol red β-D-galactopyranoside (CPRG, Sigma
Chemical Co., St. Louis, MO) as the substrate. The Tulahuen strain of
T. cruzi was kindly provided by Frederick S. Buckner (University of
Washington, Seattle, WA). Trypomastigotes were grown on
monolayers of human ﬁbroblasts, and epimastigotes were grown in
liver infusion tryptone (LIT) with 10% fetal calf serum, penicillin, and
streptomycin. Cultures assayed for β-galactosidase activity were grown
in RPMI 1640 medium without phenol red plus 10% fetal calf serum,
penicillin, and streptomycin.
Assay against the Intracellular Amastigote form of T. cruzi
Tulahuen lacZ. Drug screening against β-galactosidase-expressing
strains of T. cruzi was performed as described previously.43 The assays
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were performed in 96-well tissue culture plates (Becton Dickinson).
Human ﬁbroblasts were seeded at 2 × 103 per well in 80 μL volumes
(RPMI 1640 without phenol red) and incubated overnight. The next
day, β-galactosidase-expressing trypomastigotes (Tulahuen strain)
were added at 1.0 × 104 per well in 20 μL volumes (RPMI 1640
without phenol red). After 24 h, the synthesized compounds were
added in serial dilutions in 50 μL volumes covering a range from 300
to 0.4 μM. Each dilution was tested in triplicate. Previously, the stock
solutions were prepared in DMSO and diluted in RPMI 1640 without
phenol red. After 72 h of incubation, the plates were inspected under
an inverted microscope to ensure growth of the controls and sterility.
Then, 50 μL of the substrate containing CPRG and Nonidet P-40
(0.1% ﬁnal concentration) was added to all wells. In wells with β-
galactosidase activity, the media changed color from yellow to red, and
the color change was measured at 570 nm in an automated microplate
reader. Data were transferred into Sigma Plot to determine IC50 values.
The drug benznidazole (BZ; Sigma Chemical Co., St. Louis, MO) was
used as a positive standard in this assay, and untreated parasite cultures
were used as negative controls.
Pre-Toxicity Assays. For in vivo assays, BALB/c mice (18−20 g)
were obtained from the Faculty of Pharmaceutical Sciences of Ribeiraõ
Preto, University of Saõ Paulo and maintained under standard
conditions in the animal house of the CBEM-USP. The procedures
performed in this study were approved by the Ethics Committee on
Animal Research of The Federal University of Saõ Carlos, which are in
agreement with the International Ethics Committee on Animal
Research. In addition, the 3R principles (replacement, reduction,
reﬁnement) were followed, which propose alternative methods to the
use of animals and the reﬁnement of techniques aiming to diminish,
whenever possible, the suﬀering and the number of animals used for
scientiﬁc study. The synthesized compounds that showed in vitro
activity against T. cruzi were submitted for acute toxicity tests. This
assay was designed following the Guidelines for Testing Chemicals
with some modiﬁcations. In the assay, 6 mg of each of the compounds
(8j, 8d, 8s, 8t, 8c, 8b, 8g, 8l, 8k, and 8m) was suspended in DMSO
(30%) plus Tween 80 (10%), and compounds 8r, 22cP, 20j, 8f, 8e,
22lQ, and 8n were suspended in DMSO (20%) plus Tween 80 (10%).
The stock solutions were diluted to a ﬁnal concentration of 5 mg/mL
with sterile distilled water. Next, one female BALB/c mouse weighing
18−20 g was used for cumulative application of each test compound
via the ip route. Six doses were injected during a period of 6 h,
resulting in a ﬁnal dose of 150 mg/kg. After the administration, the
mice were observed for 48 h for signs of acute toxicity or death and
then were euthanized.
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